Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

Embracing Future Holdings / Equity Bottom-Up

<ul>
  <li>
<a href="https://smartkarma.com/entities/embracing-future-holdings-limited">Embracing Future Holdings</a> (EFH) has executed a significant strategic pivot from a precision medicine medical technology company to a diversified holding company focused on high-growth, technology-enabled lifestyle sectors, including e-commerce, Esports, and AI.</li>
  <li>Despite strong top-line growth in the most recent fiscal year, the company remains deeply unprofitable with widening net losses and severely negative margins, indicating a high-risk, high-reward profile contingent on the successful scaling of its new ventures.</li>
  <li>Valuation appears stretched, with a high price-to-book ratio and negative earnings metrics, reflecting market optimism for its new strategic direction but posing a significant risk if growth expectations are not met or profitability is not achieved.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
Embracing Future Holdings (EFH) has executed a significant strategic pivot from a precision medicine medical technology company to a diversified holding company focused on high-growth, technology-enabled lifestyle sectors, including e-commerce, Esports, and AI.
  Despite strong top-line growth in the most recent fiscal year, the company remains deeply unprofitable with widening net losses and severely negative margins, indicating a high-risk, high-reward profile contingent on the successful scaling of its new ventures.
  Valuation appears stretched, with a high price-to-book ratio and negative earnings metrics, reflecting market optimism for its new strategic direction but posing a significant risk if growth expectations are not met or profitability is not achieved.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Embracing Future Holdings (EFH SP) - Jun 2026

The New Standard in Wealth Management, Wealth Management Alliance

Wealth Management Alliance

The New Standard in Wealth Management

WMA is a Singapore-based multi-family office with a Capital Markets Services license and provide fund management and investment advisory services to a small number of global UHNW clients. We also act as incubator for single-family offices, allowing them to plug into our broader ecosystem and infrastructure, and tap on our investment professionals for advice. WMA is designed around providing truly bespoke advice to each client, rather than taking a one-size-fits-all approach that may not fit each client's investment objectives and risk tolerances. On top of that, we are designed so that we avoid any semblance of conflicts of interests by being compensated only by the client (which may include profit sharing), as opposed to the model that many of our peers adopt, which include compensation from a variety of third parties such as funds managers, distributors or banks. That, to us, is the easiest way to be firmly on the side of the client in every decision we make.

Thematic (Sector/Industry)

<ul><li>The global medical technology (MedTech) market is estimated to hit the USD1 trillion mark by mid to late 2030s, driven by aging populations, a growing incidence of chronic diseases and improving technology. Asia Pacific accounts for an estimated 20-25% of the global market, with growth underpinned by rising middle-class demand.</li><li>Singapore is a leading MedTech manufacturing and innovation hub in the region, as well as a key component of the country’s biomedical sector.</li><li>Singapore’s overall MedTech industry is highly vibrant, given the presence of the world’s top multinationals operating here, to account for some 80-90% of the industry’s total output.</li></ul>

The global medical technology (MedTech) market is estimated to hit the USD1 trillion mark by mid to late 2030s, driven by aging populations, a growing incidence of chronic diseases and improving technology. Asia Pacific accounts for an estimated 20-25% of the global market, with growth underpinned by rising middle-class demand.Singapore is a leading MedTech manufacturing and innovation hub in the region, as well as a key component of the country’s biomedical sector.Singapore’s overall MedTech industry is highly vibrant, given the presence of the world’s top multinationals operating here, to account for some 80-90% of the industry’s total output.

Singapore Medtech Industry: High Growth but a Critical Mass Will Hinge on More Company Listings

SGX Market Strategist, Equity & Fixed Income, Singapore Exchange Ltd (SGX)

Geoff Howie

SGX Market Strategist, Equity & Fixed Income

Asia’s leading multi-asset exchange

Singapore Exchange Ltd (SGX)

Singapore Exchange is Asia’s leading and trusted market infrastructure, facilitating the exchange of capital and ideas to create value for people, businesses and economies. As a multi-asset exchange operating equity, fixed income and derivatives markets to the highest regulatory standards, SGX is a vertically integrated business that provides listing, trading, clearing, settlement, depository and data services.

With about 40% of listed companies and over 80% of listed bonds originating outside of Singapore as well as established linkages across the region and in Europe, SGX is Asia’s most international and connected exchange. Offering a full suite of derivatives products across Asian equity indices, commodities and currencies, SGX is the world’s most liquid international market for the benchmark equity indices of China, India, Japan and ASEAN.

As Asia’s pioneering central counterparty, SGX is globally recognised for its risk management and clearing capabilities, and was one of the first globally to adopt the Principles for Financial Market Infrastructure.

Headquartered in AAA-rated Singapore, SGX has over 800 employees including offices in Beijing, Chicago, Hong Kong, London, New York, Mumbai, San Francisco, Shanghai and Tokyo.

<ul><li>Singapore Telecommunications led buybacks with 27.1 million shares at S$4.26, part of a S$2 billion programme.</li><li>Embracing Future Holdings' Chen Lu increased stake to 9.17% with 83 million shares for S$3.9 million.</li><li>Amova Asset Management Asia raised Frencken stake to 6.03%, coinciding with FY26 revenue and profit expectations.</li></ul>

Singapore Telecommunications led buybacks with 27.1 million shares at S$4.26, part of a S$2 billion programme.Embracing Future Holdings' Chen Lu increased stake to 9.17% with 83 million shares for S$3.9 million.Amova Asset Management Asia raised Frencken stake to 6.03%, coinciding with FY26 revenue and profit expectations.

Buyback Momentum Continues, Director Acquisitions Broaden

<figure class="editor-figure mceNonEditable"><img src="https://api2.sgx.com/sites/default/files/2022-04/Biolidics-CEO.jpg" class="editor-image img-responsive"></figure>
<div class="content-caption">Biolidics CEO</div>
<p></p>
<p>For technology veteran Song Tang Yih, one of his biggest career aspirations has been to grow into a “Level 5” executive, a concept coined by renowned management guru Jim Collins in his bestseller, “Good to Great”.<br><br>“Jim Collins defines a Level 5 leader as one who “builds enduring greatness through a paradoxical blend of personal humility and professional will” - that really resonates with me,” said the Chief Executive Officer of SGX-listed medtech company Biolidics Ltd.&nbsp;<br><br>According to Collins, Level 5 leadership is not just about humility or modesty - it’s also about possessing “a ferocious resolve” and “an almost stoic determination” to do whatever is required to make the organisation&nbsp;great.<br><br>“As I strive towards this leadership goal, Biolidics will develop the culture of building trust and open communication,” Song added.&nbsp;<br><br>“In such an environment, criticism and failure will be acknowledged objectively, due diligence will be conducted professionally, and subsequent actions can then be carried out with determination.”<br><br>A Bachelor of Science graduate from the National University of Singapore, Song has spent almost two decades of his career in the information technology sector.&nbsp;<br><br>He has held senior management roles in various tech companies, including Vice President, Asia Pacific of Nasdaq-listed Palo Alto Networks, as well as Executive Chairman of SGX-listed Metech International Ltd, before his current appointment as CEO of Biolidics in September 2021.<br><br>“Biolidics is a tech-driven company that offers promising technology for oncology precision medicine. Its ClearCell® FX1 System intrigues me, and I want to contribute towards the development of less invasive treatments and care for cancer patients,” Song noted.<br><br>ClearCell® FX1 is a fully automated device for cell retrieval that uses a novel, patented technology to separate and enrich wholly intact and viable circulating tumour cells, or CTCs, from small amounts of blood. It is driven by the Group’s CTChip®FR1 biochip, which is a single-use microfluidic biochip.<br><br>Liquid biopsies - or the analysis of CTCs in blood samples - have many applications through the various stages of a patient's cancer journey, ranging from cancer screening and staging, to personalised treatment and post-cancer monitoring.<br><br>“Biolidics possesses strong fundamentals in product innovation and development - innovative technologies and a rich talent repository are the two critical success factors to growing a company,” he added.<br><br>“On my part, I bring to Biolidics the experience of turning ideas into commercial execution, as well as implementing customer-focused strategies. Such a combination augurs well for our future.”<br><br><strong>Boosting Revenue Streams</strong><br><br>Incorporated in 2009 and listed on SGX Catalist in 2018, Biolidics is a precision medicine medical technology company developing a portfolio of innovative diagnostic solutions to reduce healthcare costs and improve clinical outcomes. &nbsp;<br><br>The Group also operates a CAP- (College of American Pathologists) accredited clinical laboratory in Singapore that offers a wide range of tests. In addition, it has formed an infectious diseases division to develop diagnostic test kits with technology partners and in-vitro diagnostics (IVD) manufacturers. Its quality assurance capabilities have been recognised through its ISO 13485 certification, CE-IVD, US FDA Class I registration and NMPA Class I registration. &nbsp;<br><br>Looking ahead, Biolidics will focus on growing revenue streams from its three business divisions - cancer diagnostics, infectious diseases diagnostics and laboratory diagnostics services, Song noted.<br><br>For cancer diagnostics, the Group aims to develop complete liquid biopsy solutions, to enable extracting information from cancer patient’s blood specimens at both the cellular and molecular levels, to provide timely insights to manage cancer care via laboratory-developed tests (LDTs), also known as laboratory assays.&nbsp;<br><br>“Such LDTs are a cheaper, safer and simpler alternative to traditional methods,&nbsp;which involve tissue biopsies - surgical processes that are not only invasive to the patient, they are expensive and difficult to repeat,” Song noted.<br><br>“And once clinically approved, the LDTs can potentially boost the sales potential of our products, because each LDT will require the use of one CTChip® FR1 biochip as well as other consumables.”<br><br>According to data from Statista, cancer accounted for nearly 10 million, or nearly one in six, deaths globally in 2020. This figure is expected to rise to 16 million by 2040. Incidence rates for the disease&nbsp;are expected to increase from just under 20 million new cases per year in 2020 to over 30 million new cases per year by 2040.<br><br>For its infectious diseases diagnostics segment, Biolidics is developing diagnostic test kits through partnerships with technology partners and IVD manufacturers. Since the start of the COVID-19 pandemic, the Group has introduced various types of rapid test kits for the detection of SARS-CoV-2.&nbsp;<br><br>In particular, it is starting commercial production for its ClearEpi NAB Test that is developed with technology licensed from the commercialisation arm of Singapore's Agency for Science, Technology and Research (A*STAR). This test detects human IgG neutralising antibodies, which indicate an individual's protective immunity against Covid-19.<br><br>“Even with encouraging news on global vaccine roll-out programmes, the importance of reliable, accessible testing continues to be essential to public health policy responses towards COVID‑19,” Song pointed out.<br><br>“And as the global economy re-opens with the resumption of economic and community activities on a wider scale, we expect testing applications for COVID-19 to continue to play a vital role in the “new-normal”, for screening purposes, as well as other forms of routine, asymptomatic and travel-related testing.”<br><br><strong>Meeting Stringent Regulations</strong><br><br>In terms of laboratory diagnostics services, Biolidics’ Singapore-based lab provides a comprehensive suite of clinical diagnostic tests, including genetic tests and other cancer-related diagnostic tests. These tests are conducted in-house as well as in partnership with global partners and institutions, Song said.<br><br>In December 2021, its lab was granted approval by Singapore’s Ministry of Health to provide medical microbiology (molecular microbiology) services, including SARS-CoV-2 polymerase chain reaction (PCR) testing for COVID-19.<br><br>“To create new revenue streams for our lab diagnostics services, we’re also developing a strong pipeline of proprietary biomarker tests for cancer immunotherapy treatment, recurrence monitoring and cancer screening,” he added.<br><br>Apart from laying the foundation for the Group’s future growth, Song is also focused on its Environmental, Social and Governance (ESG) targets.&nbsp;“Biolidics’ products and business activities are regulated by various laws governing medical devices in the countries that it sells its products in,” he noted.<br><br>“We are subject to extensive supervision by governments and other agencies in various aspects of our operations, including licensing and certification requirements, product registration requirements, quality and safety standards, as well as periodic renewal and reassessment procedures.”<br><br>While there is much to keep Song up till the wee hours, he enjoys the challenges that running the organisation offers.<br><br>“I’m constantly planning two to three steps ahead, in the areas of shareholder interests, commercial issues, as well as working with staff to resolve issues in innovation and business execution,” he said. &nbsp;<br><br>“These are broad areas that give me “butterflies in my stomach”.&nbsp; Such sensations are good as they indicate that I’m not being complacent, but getting ready to manage uncertainties.”<br><br>When the 58-year-old is not at work, he is focused on living a simple life. “I like simplicity - whether it’s eating meals with my family, cuddling up to my golden retriever, or an evening stroll around the neighbourhood,” he said. “I always remind myself to live in the present and enjoy these moments.”<br><br>As for advice to his staff and children, Song encourages them to develop an athlete’s mindset.&nbsp;<br><br>“An athlete is disciplined, trains hard and performs his best in a team. He also strives to improve his results with every race. Whether he wins or loses, an athlete manages his emotions, understands his strengths and weaknesses, and is committed to the pursuit of excellence,” he added.<br><br>“These are all qualities that are important in developing your character and tackling the challenges in life.”<br><br><strong>Biolidics Ltd</strong><br><br>Incorporated in 2009, Biolidics is a precision medicine medical technology company with a focus in developing a portfolio of innovative diagnostic solutions to lower healthcare costs and improve clinical outcomes. Biolidics has developed and commercialised the ClearCell® FX1 System, a fully automated CEIVD medical device which relies on a novel, patented technology to separate and enrich cancer cells from blood, allowing users of the system to perform liquid biopsies to test for the presence of cancer cells (specifically circulating tumour cells, or CTCs) in blood. Biolidics also has a CAP-accredited clinical laboratory in Singapore that offers a wide range of tests, which could potentially accelerate its revenue growth and execution strategy in cancer diagnostics. In addition, Biolidics has formed an infectious diseases division to develop test kits with various diagnostic partners. Biolidics’ quality assurance capabilities have been recognised through its ISO 13485 certification, CE-IVD, US FDA Class I registration and NMPA Class I registration.<br><br>The company website is: <a href="http://www.biolidics.com" target="_blank" rel="noopener"><strong>www.biolidics.com</strong></a><br><br>Click&nbsp;<a href="https://www.sgx.com/securities/equities/8YY" target="_blank" rel="noopener"><strong>here</strong>&nbsp;</a>for the company's StockFacts page.<br><br>For the full year ended 31 December 2021 financial results, click&nbsp;<a href="https://links.sgx.com/1.0.0/corporate-announcements/0NKVPSR3PANSRGIN/705272_Biolidics%20FY2021%20Results%20Announcement%20Final.pdf" target="_blank" rel="noopener"><strong>here</strong></a>.</p>
<p><br><strong>About&nbsp;kopi-C: the Company brew</strong></p>
<p><strong>Text: Jennifer Tan-Stanisic</strong><br><strong>Photo: Company file</strong><br><br><em>kopi-C&nbsp;</em>is a regular column on the SGX Research website that features C-level executives of leading companies listed on Singapore Exchange. These interviews are profiles of senior management aimed at helping investors better understand the individuals who run these corporations.<br><br>For previous editions of&nbsp;<em>kopi-C: the Company brew,</em>&nbsp;please click&nbsp;<a href="https://www.sgx.com/research-education/market-dialogues" target="_blank" rel="noopener">here</a>. &nbsp;<br><br>For more information, or if you would like your senior executives to be featured on SGX Market Dialogues, please send suggestions to&nbsp;<a href="https://www.sgx.com/jennifer.t@sgx.com" target="_blank" rel="noopener">jennifer.t@sgx.com</a>.</p>


Biolidics CEO

For technology veteran Song Tang Yih, one of his biggest career aspirations has been to grow into a “Level 5” executive, a concept coined by renowned management guru Jim Collins in his bestseller, “Good to Great”.  “Jim Collins defines a Level 5 leader as one who “builds enduring greatness through a paradoxical blend of personal humility and professional will” - that really resonates with me,” said the Chief Executive Officer of SGX-listed medtech company Biolidics Ltd.&nbsp;  According to Collins, Level 5 leadership is not just about humility or modesty - it’s also about possessing “a ferocious resolve” and “an almost stoic determination” to do whatever is required to make the organisation&nbsp;great.  “As I strive towards this leadership goal, Biolidics will develop the culture of building trust and open communication,” Song added.&nbsp;  “In such an environment, criticism and failure will be acknowledged objectively, due diligence will be conducted professionally, and subsequent actions can then be carried out with determination.”  A Bachelor of Science graduate from the National University of Singapore, Song has spent almost two decades of his career in the information technology sector.&nbsp;  He has held senior management roles in various tech companies, including Vice President, Asia Pacific of Nasdaq-listed Palo Alto Networks, as well as Executive Chairman of SGX-listed Metech International Ltd, before his current appointment as CEO of Biolidics in September 2021.  “Biolidics is a tech-driven company that offers promising technology for oncology precision medicine. Its ClearCell® FX1 System intrigues me, and I want to contribute towards the development of less invasive treatments and care for cancer patients,” Song noted.  ClearCell® FX1 is a fully automated device for cell retrieval that uses a novel, patented technology to separate and enrich wholly intact and viable circulating tumour cells, or CTCs, from small amounts of blood. It is driven by the Group’s CTChip®FR1 biochip, which is a single-use microfluidic biochip.  Liquid biopsies - or the analysis of CTCs in blood samples - have many applications through the various stages of a patient's cancer journey, ranging from cancer screening and staging, to personalised treatment and post-cancer monitoring.  “Biolidics possesses strong fundamentals in product innovation and development - innovative technologies and a rich talent repository are the two critical success factors to growing a company,” he added.  “On my part, I bring to Biolidics the experience of turning ideas into commercial execution, as well as implementing customer-focused strategies. Such a combination augurs well for our future.”  Boosting Revenue Streams  Incorporated in 2009 and listed on SGX Catalist in 2018, Biolidics is a precision medicine medical technology company developing a portfolio of innovative diagnostic solutions to reduce healthcare costs and improve clinical outcomes. &nbsp;  The Group also operates a CAP- (College of American Pathologists) accredited clinical laboratory in Singapore that offers a wide range of tests. In addition, it has formed an infectious diseases division to develop diagnostic test kits with technology partners and in-vitro diagnostics (IVD) manufacturers. Its quality assurance capabilities have been recognised through its ISO 13485 certification, CE-IVD, US FDA Class I registration and NMPA Class I registration. &nbsp;  Looking ahead, Biolidics will focus on growing revenue streams from its three business divisions - cancer diagnostics, infectious diseases diagnostics and laboratory diagnostics services, Song noted.  For cancer diagnostics, the Group aims to develop complete liquid biopsy solutions, to enable extracting information from cancer patient’s blood specimens at both the cellular and molecular levels, to provide timely insights to manage cancer care via laboratory-developed tests (LDTs), also known as laboratory assays.&nbsp;  “Such LDTs are a cheaper, safer and simpler alternative to traditional methods,&nbsp;which involve tissue biopsies - surgical processes that are not only invasive to the patient, they are expensive and difficult to repeat,” Song noted.  “And once clinically approved, the LDTs can potentially boost the sales potential of our products, because each LDT will require the use of one CTChip® FR1 biochip as well as other consumables.”  According to data from Statista, cancer accounted for nearly 10 million, or nearly one in six, deaths globally in 2020. This figure is expected to rise to 16 million by 2040. Incidence rates for the disease&nbsp;are expected to increase from just under 20 million new cases per year in 2020 to over 30 million new cases per year by 2040.  For its infectious diseases diagnostics segment, Biolidics is developing diagnostic test kits through partnerships with technology partners and IVD manufacturers. Since the start of the COVID-19 pandemic, the Group has introduced various types of rapid test kits for the detection of SARS-CoV-2.&nbsp;  In particular, it is starting commercial production for its ClearEpi NAB Test that is developed with technology licensed from the commercialisation arm of Singapore's Agency for Science, Technology and Research (A*STAR). This test detects human IgG neutralising antibodies, which indicate an individual's protective immunity against Covid-19.  “Even with encouraging news on global vaccine roll-out programmes, the importance of reliable, accessible testing continues to be essential to public health policy responses towards COVID‑19,” Song pointed out.  “And as the global economy re-opens with the resumption of economic and community activities on a wider scale, we expect testing applications for COVID-19 to continue to play a vital role in the “new-normal”, for screening purposes, as well as other forms of routine, asymptomatic and travel-related testing.”  Meeting Stringent Regulations  In terms of laboratory diagnostics services, Biolidics’ Singapore-based lab provides a comprehensive suite of clinical diagnostic tests, including genetic tests and other cancer-related diagnostic tests. These tests are conducted in-house as well as in partnership with global partners and institutions, Song said.  In December 2021, its lab was granted approval by Singapore’s Ministry of Health to provide medical microbiology (molecular microbiology) services, including SARS-CoV-2 polymerase chain reaction (PCR) testing for COVID-19.  “To create new revenue streams for our lab diagnostics services, we’re also developing a strong pipeline of proprietary biomarker tests for cancer immunotherapy treatment, recurrence monitoring and cancer screening,” he added.  Apart from laying the foundation for the Group’s future growth, Song is also focused on its Environmental, Social and Governance (ESG) targets.&nbsp;“Biolidics’ products and business activities are regulated by various laws governing medical devices in the countries that it sells its products in,” he noted.  “We are subject to extensive supervision by governments and other agencies in various aspects of our operations, including licensing and certification requirements, product registration requirements, quality and safety standards, as well as periodic renewal and reassessment procedures.”  While there is much to keep Song up till the wee hours, he enjoys the challenges that running the organisation offers.  “I’m constantly planning two to three steps ahead, in the areas of shareholder interests, commercial issues, as well as working with staff to resolve issues in innovation and business execution,” he said. &nbsp;  “These are broad areas that give me “butterflies in my stomach”.&nbsp; Such sensations are good as they indicate that I’m not being complacent, but getting ready to manage uncertainties.”  When the 58-year-old is not at work, he is focused on living a simple life. “I like simplicity - whether it’s eating meals with my family, cuddling up to my golden retriever, or an evening stroll around the neighbourhood,” he said. “I always remind myself to live in the present and enjoy these moments.”  As for advice to his staff and children, Song encourages them to develop an athlete’s mindset.&nbsp;  “An athlete is disciplined, trains hard and performs his best in a team. He also strives to improve his results with every race. Whether he wins or loses, an athlete manages his emotions, understands his strengths and weaknesses, and is committed to the pursuit of excellence,” he added.  “These are all qualities that are important in developing your character and tackling the challenges in life.”  Biolidics Ltd  Incorporated in 2009, Biolidics is a precision medicine medical technology company with a focus in developing a portfolio of innovative diagnostic solutions to lower healthcare costs and improve clinical outcomes. Biolidics has developed and commercialised the ClearCell® FX1 System, a fully automated CEIVD medical device which relies on a novel, patented technology to separate and enrich cancer cells from blood, allowing users of the system to perform liquid biopsies to test for the presence of cancer cells (specifically circulating tumour cells, or CTCs) in blood. Biolidics also has a CAP-accredited clinical laboratory in Singapore that offers a wide range of tests, which could potentially accelerate its revenue growth and execution strategy in cancer diagnostics. In addition, Biolidics has formed an infectious diseases division to develop test kits with various diagnostic partners. Biolidics’ quality assurance capabilities have been recognised through its ISO 13485 certification, CE-IVD, US FDA Class I registration and NMPA Class I registration.  The company website is: www.biolidics.com  Click&nbsp;here&nbsp;for the company's StockFacts page.  For the full year ended 31 December 2021 financial results, click&nbsp;here.
 About&nbsp;kopi-C: the Company brew
Text: Jennifer Tan-Stanisic Photo: Company file  kopi-C&nbsp;is a regular column on the SGX Research website that features C-level executives of leading companies listed on Singapore Exchange. These interviews are profiles of senior management aimed at helping investors better understand the individuals who run these corporations.  For previous editions of&nbsp;kopi-C: the Company brew,&nbsp;please click&nbsp;here. &nbsp;  For more information, or if you would like your senior executives to be featured on SGX Market Dialogues, please send suggestions to&nbsp;jennifer.t@sgx.com.

Biolidics: Pushing the Frontiers of Medical Technology 

<p><i><b>These equity research reports are not written by the SGX.</b> SGX supports the distribution of the research reports by external contributors. Please refer to the Disclaimer in the attached report.</i></p><div>
<div>
<div>
<div>
<h2>Biolidics Ltd</h2>
<div>
<div>
<div>
<div>
<p><strong>The rise of rapid test kits</strong></p>
<div>
<div>
<div>
<div>
<ul>
<li>
<p>Biolidics is a med tech firm that develops and sells diagnostic systems and other lab-developed tests for liquid biopsy on circulating tumour cells (CTCs).</p>
</li>
<li>
<p>It recently diversified into Covid-19 antibody testing, with regulatory approvals and distributorships already secured in some markets.</p>
</li>
<li>
<p>Management expects its rapid test kits and various distributorships to contribute positively to FY20F revenue. It recorded FY19 net loss of S$4.8m.</p>
</li>
</ul>
<div>
<div>
<div>
<div>
<p><strong>Established background in liquid biopsy diagnostics</strong></p>
<p>Established in 2009 and listed on the Singapore Exchange since Dec 2018, Biolidics Ltd is a medical technology company spun off from a university-affiliated research centre. It has developed and commercialised a fully-automated in vitro diagnostic (IVD) medical device (ClearCell® FX1 System) and the CTChip® FR1 biochip, to perform liquid biopsies to test for the presence of circulating tumour cells (CTCs). This technology enables the separation and enrichment of cancer cells from 7.5ml of blood in under two hours (vs. 7- 30 days turnaround time for Guardant Health’s programmes), according to Biolidics.</p>
<p><strong>Diversifying into Covid-19 testing</strong></p>
<p>On 30 Mar, Biolidics announced that it had partnered with a Chinese supplier to customise and manufacture Covid-19 antibody test kits. The group has since received approval from some authorities, including Singapore’s Health Sciences Authority, EU’s Conformité Européene (CE) marking and the U.S. Food and Drug Administration (FDA); it has also secured non-exclusive distributorships in HK, the US and selected ASEAN markets. Unlike the reverse transcriptase-polymerase chain reaction (RT-PCR) test which is the global standard for active infections testing, Biolidics’s test kits serve to detect past infections using both IgG and IgM antibodies. Hence, they are not used for confirmatory testing nor as the sole basis for diagnosis, and are limited to testing in labs or at the point-of-care. These rapid test kits could be deployed as a screening tool (according to Biolidics and industry sources) given its quick turnaround (more than 95% accuracy in 10 minutes, based on its validation data) and cost effectiveness.</p>
<p><strong>Could the new rapid test kits be a game changer?</strong></p>
<p>Management said in its SGX announcement that it expects the Covid-19 test kits and various distributorships to contribute positively to its FY20F revenue, though the financial impact may not be quantified as the volume and timing of orders cannot be ascertained. The group has net cash of S$6.0m as at end-FY19 and currently trades at 13.1x FY19 P/BV.</p>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>

These equity research reports are not written by the SGX. SGX supports the distribution of the research reports by external contributors. Please refer to the Disclaimer in the attached report.



Biolidics Ltd




The rise of rapid test kits






Biolidics is a med tech firm that develops and sells diagnostic systems and other lab-developed tests for liquid biopsy on circulating tumour cells (CTCs).


It recently diversified into Covid-19 antibody testing, with regulatory approvals and distributorships already secured in some markets.


Management expects its rapid test kits and various distributorships to contribute positively to FY20F revenue. It recorded FY19 net loss of S$4.8m.






Established background in liquid biopsy diagnostics
Established in 2009 and listed on the Singapore Exchange since Dec 2018, Biolidics Ltd is a medical technology company spun off from a university-affiliated research centre. It has developed and commercialised a fully-automated in vitro diagnostic (IVD) medical device (ClearCell® FX1 System) and the CTChip® FR1 biochip, to perform liquid biopsies to test for the presence of circulating tumour cells (CTCs). This technology enables the separation and enrichment of cancer cells from 7.5ml of blood in under two hours (vs. 7- 30 days turnaround time for Guardant Health’s programmes), according to Biolidics.
Diversifying into Covid-19 testing
On 30 Mar, Biolidics announced that it had partnered with a Chinese supplier to customise and manufacture Covid-19 antibody test kits. The group has since received approval from some authorities, including Singapore’s Health Sciences Authority, EU’s Conformité Européene (CE) marking and the U.S. Food and Drug Administration (FDA); it has also secured non-exclusive distributorships in HK, the US and selected ASEAN markets. Unlike the reverse transcriptase-polymerase chain reaction (RT-PCR) test which is the global standard for active infections testing, Biolidics’s test kits serve to detect past infections using both IgG and IgM antibodies. Hence, they are not used for confirmatory testing nor as the sole basis for diagnosis, and are limited to testing in labs or at the point-of-care. These rapid test kits could be deployed as a screening tool (according to Biolidics and industry sources) given its quick turnaround (more than 95% accuracy in 10 minutes, based on its validation data) and cost effectiveness.
Could the new rapid test kits be a game changer?
Management said in its SGX announcement that it expects the Covid-19 test kits and various distributorships to contribute positively to its FY20F revenue, though the financial impact may not be quantified as the volume and timing of orders cannot be ascertained. The group has net cash of S$6.0m as at end-FY19 and currently trades at 13.1x FY19 P/BV.

















Non-SGX Report: Biolidics Ltd: The Rise of Rapid Test Kits

Singapore

Embracing Future Holdings is a Singapore-based company incorporated in 2009. Initially a precision medicine medical technology company, it developed diagnostic solutions for cancer and infectious diseases, including the ClearCell® FX1 System. The company has since diversified into technology-enabled lifestyle businesses, encompassing Multi-Channel Networks (MCN), live streaming social e-commerce, Esports, Green Energy, and Artificial Intelligence (AI) agent sectors.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Embracing Future Holdings (EFH SP)

Primer: Embracing Future Holdings (EFH SP) - Jun 2026

Embracing Future Holdings (EFH) has executed a significant strategic pivot from a precision medicine medical technology company to a...

αSK Primers

Singapore Medtech Industry: High Growth but a Critical Mass Will Hinge on More Company Listings

The global medical technology (MedTech) market is estimated to hit the USD1 trillion mark by mid to late 2030s, driven by aging populations, a...

Wealth Management Alliance

Buyback Momentum Continues, Director Acquisitions Broaden

Singapore Telecommunications led buybacks with 27.1 million shares at S$4.26, part of a S$2 billion programme. Embracing Future Holdings' Chen Lu...

Singapore Exchange Ltd (SGX)

Biolidics: Pushing the Frontiers of Medical Technology

For technology veteran Song Tang Yih, one of his biggest career aspirations has been to grow into a “Level 5” executive, a concept coined by...

Singapore Exchange Ltd (SGX)

Non-SGX Report: Biolidics Ltd: The Rise of Rapid Test Kits

These equity research reports are not written by the SGX. SGX supports the distribution of the research reports by external contributors. Please...

Singapore Exchange Ltd (SGX)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)